AI Insight
Ozempic and similar GLP-1 drugs appear to reduce cravings not only for food but also for alcohol and other addictive substances. Scientists have identified the lateral septum, a brain region dense with GLP-1 receptors, as a potential key control center that links memories and environmental cues to reward-seeking behavior. This region may regulate the transition from thinking about a reward to actively pursuing it.
Why it matters
The findings suggest that GLP-1-based medications could be repurposed to treat various forms of addiction beyond their current use for obesity and diabetes. Understanding the lateral septum's role in craving could lead to targeted therapies for substance abuse disorders.
Understand the Science
Ozempic-like drugs appear to weaken more than hunger—they may also reduce cravings for alcohol and other addictive substances. Scientists are increasingly tracing this effect to the lateral septum, a brain region that helps connect memories and surroundings with rewarding experiences. Packed with GLP-1 receptors, it may act as a crucial control point between thinking about a reward and feeling compelled to pursue it. The discovery could open new approaches to treating addiction as well as obesity.
Source: Ozempic may have revealed the brain’s hidden “craving center”